COMMUNITY ANNOUNCEMENT RE: PPE & ACCESS TO RAPID TESTING
COMMUNITY ANNOUNCEMENT From Dr. Marie Zhivago
Hello FilAmChamber 2.0 San Diego,
Are you, a family member or friend needing PPEs and COVID19 Test kits. *Especially for the elderly. I am now part of a team dedicated to Medical Supplies. Local with global partnerships in Medical Supplies. I have come to decide to do this based on my experience and path from Healthcare, Education, and City service positions. Especially during a global pandemic. Filipinos historically encompass all levels of the Healthcare system. The barriers are needed to keep them alive now and in the future. The global healthcare market is run by control groups especially in the USA, China, India, etc. Without strategic contact groups and networks, we face delays and dilemmas in the procurement of supplies, here for our community.
CareStart™ COVID-19 Antigen test kit using NanoAct™ launched in the U.S.
TOKYO, Dec. 8, 2020 /PRNewswire/ -- CareStart™ COVID-19 Antigen test kit developed by Access Bio, Inc., using Asahi Kasei's NanoAct™ cellulose nanobeads, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), and its sale in the U.S. has begun.
NanoAct™ colored cellulose nanobeads were developed by Asahi Kasei by utilizing its core technology of cellulose processing. They are currently used as labels for lateral flow immunochromatographic assays, mainly for influenza. NanoAct™ was adopted by Access Bio, Inc. for use in CareStart™ COVID-19 Ag as it is available in a wide range of colors and enables better visibility of test lines, which improves usability.
The continuing spread of COVID-19 has raised the importance of rapid screening. Demand for rapid test kits is rising because unlike polymerase chain reaction (PCR) tests, they require no special equipment. Access Bio, Inc., the world's leading manufacturer of rapid test kits for malaria, developed CareStart™ COVID-19 Ag to rapidly detect antigens of SARS-CoV-2, the virus which causes COVID-19.
Clinical evaluations indicate that CareStart™ COVID-19 Ag provides a sensitivity of 88.4% and specificity of 100%, which is comparable to reverse transcription (RT)-PCR testing. Furthermore, CareStart™ COVID-19 Ag provides results in 10 minutes while PCR generally takes 1 or 2 days. In addition, the availability of NanoAct™ in multi-color variation enables different colors to be shown, such as blue for the test line (T in the figure below) and red for the control line (C), which allows easier judgment as a user-friendly test kit.
CareStart™ COVID-19 Ag has also obtained CE Mark certification, and it is scheduled to be launched in Europe, Southeast Asia, and Africa.
Contact: Dr. Marie Zhivago PH 619.701.3802 | Email: firstname.lastname@example.org Facebook: @mrszhivago | LinkedIn: @drzhivago